Sei Investments Co. Has $2.06 Million Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Sei Investments Co. reduced its holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 1.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 218,914 shares of the biopharmaceutical company’s stock after selling 3,359 shares during the period. Sei Investments Co.’s holdings in Amicus Therapeutics were worth $2,062,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Sciencast Management LP bought a new stake in Amicus Therapeutics in the fourth quarter valued at approximately $100,000. Semanteon Capital Management LP grew its holdings in shares of Amicus Therapeutics by 40.9% in the 4th quarter. Semanteon Capital Management LP now owns 149,156 shares of the biopharmaceutical company’s stock valued at $1,405,000 after buying an additional 43,288 shares during the period. Teacher Retirement System of Texas increased its position in shares of Amicus Therapeutics by 18.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,927 shares of the biopharmaceutical company’s stock valued at $621,000 after buying an additional 10,218 shares in the last quarter. Xponance Inc. raised its stake in Amicus Therapeutics by 11.9% during the 4th quarter. Xponance Inc. now owns 21,216 shares of the biopharmaceutical company’s stock worth $200,000 after buying an additional 2,249 shares during the period. Finally, Intech Investment Management LLC lifted its holdings in Amicus Therapeutics by 59.7% during the fourth quarter. Intech Investment Management LLC now owns 124,704 shares of the biopharmaceutical company’s stock worth $1,175,000 after acquiring an additional 46,633 shares in the last quarter.

Amicus Therapeutics Trading Down 6.3 %

Shares of Amicus Therapeutics stock opened at $7.50 on Friday. The company has a debt-to-equity ratio of 2.01, a quick ratio of 2.42 and a current ratio of 3.39. Amicus Therapeutics, Inc. has a 52 week low of $7.39 and a 52 week high of $12.65. The stock has a 50 day moving average price of $9.12 and a two-hundred day moving average price of $9.85. The stock has a market capitalization of $2.30 billion, a PE ratio of -41.67, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on FOLD shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a research note on Wednesday, January 15th. Morgan Stanley reaffirmed an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a research report on Friday, December 13th. Needham & Company LLC reissued a “hold” rating on shares of Amicus Therapeutics in a research report on Thursday, February 20th. StockNews.com cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Thursday, February 20th. Finally, Wells Fargo & Company decreased their price target on shares of Amicus Therapeutics from $18.00 to $17.00 and set an “overweight” rating for the company in a research note on Thursday, February 20th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat, Amicus Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.